LeMaitre Vascular (NASDAQ:LMAT) Raised to “Buy” at StockNews.com

StockNews.com upgraded shares of LeMaitre Vascular (NASDAQ:LMAT) from a hold rating to a buy rating in a report released on Friday morning.

LMAT has been the topic of a number of other reports. JMP Securities upped their target price on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the stock a market outperform rating in a research report on Friday, May 3rd. Roth Mkm reaffirmed a buy rating and issued a $100.00 target price on shares of LeMaitre Vascular in a research report on Friday, May 31st. Stifel Nicolaus raised shares of LeMaitre Vascular from a hold rating to a buy rating and upped their target price for the stock from $59.00 to $75.00 in a research report on Friday, April 26th. Roth Capital raised shares of LeMaitre Vascular to a strong-buy rating in a research report on Friday, May 31st. Finally, Barrington Research upped their target price on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the stock an outperform rating in a research report on Friday, May 3rd. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus target price of $77.57.

LeMaitre Vascular Trading Up 1.3 %

Shares of LeMaitre Vascular stock opened at $80.09 on Friday. The company’s fifty day simple moving average is $73.01 and its two-hundred day simple moving average is $64.77. The company has a market cap of $1.80 billion, a P/E ratio of 53.04, a PEG ratio of 2.44 and a beta of 0.89. LeMaitre Vascular has a 12-month low of $44.27 and a 12-month high of $81.68.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.05. The business had revenue of $53.48 million for the quarter, compared to the consensus estimate of $51.50 million. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.57%. The company’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.27 EPS. Analysts predict that LeMaitre Vascular will post 1.77 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, May 30th. Investors of record on Thursday, May 16th were paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.80%. The ex-dividend date of this dividend was Wednesday, May 15th. LeMaitre Vascular’s payout ratio is 42.38%.

Insider Buying and Selling

In related news, CEO George W. Lemaitre sold 68,906 shares of the company’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $75.70, for a total value of $5,216,184.20. Following the transaction, the chief executive officer now owns 2,133,428 shares in the company, valued at approximately $161,500,499.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other LeMaitre Vascular news, CEO George W. Lemaitre sold 68,906 shares of the company’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $75.70, for a total transaction of $5,216,184.20. Following the transaction, the chief executive officer now owns 2,133,428 shares in the company, valued at approximately $161,500,499.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bridget A. Ross sold 5,500 shares of the company’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $77.99, for a total transaction of $428,945.00. Following the transaction, the director now owns 2,278 shares in the company, valued at approximately $177,661.22. The disclosure for this sale can be found here. Insiders have sold a total of 87,431 shares of company stock worth $6,627,520 in the last quarter. Corporate insiders own 10.79% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

Several institutional investors have recently made changes to their positions in LMAT. Mesirow Institutional Investment Management Inc. bought a new position in shares of LeMaitre Vascular in the 4th quarter worth approximately $8,837,000. Ranger Investment Management L.P. lifted its stake in shares of LeMaitre Vascular by 15.8% in the 3rd quarter. Ranger Investment Management L.P. now owns 898,822 shares of the medical instruments supplier’s stock worth $48,968,000 after purchasing an additional 122,601 shares during the period. Congress Asset Management Co. MA lifted its stake in shares of LeMaitre Vascular by 17.0% in the 4th quarter. Congress Asset Management Co. MA now owns 594,672 shares of the medical instruments supplier’s stock worth $33,754,000 after purchasing an additional 86,293 shares during the period. Summit Creek Advisors LLC lifted its stake in shares of LeMaitre Vascular by 37.8% in the 4th quarter. Summit Creek Advisors LLC now owns 228,501 shares of the medical instruments supplier’s stock worth $12,970,000 after purchasing an additional 62,737 shares during the period. Finally, Janus Henderson Group PLC lifted its stake in shares of LeMaitre Vascular by 554.7% in the 1st quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock worth $3,697,000 after purchasing an additional 47,218 shares during the period. Institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.